Clinical Trials

Please check with your doctor or call 1-855-HCH-HOPE (424-4673) to find out if you qualify for any of these studies.

Trial #: D5162C00042 (COMPEL) Now Enrolling
Sponsor: AstraZeneca
Trial Sub-Type: Locally advanced (clinical stage IIIB or IIIC) or metastatic NSCLC (clinical stage IVA or IVB) or recurrent NSCLC
Title and Key Inclusion/Exclusion Criteria: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Pemetrexed Chemotherapy Plus Osimertinib Versus Platinum Plus Pemetrexed Chemotherapy Plus Placebo in Patients with EGFRm, Locally Advanced or Metastatic NSCLC who have Progressed Extracranially following First-Line Osimertinib Therapy.

Trial #: D5162C00048 (TARGET)
Sponsor: AstraZeneca
Trial Sub-Type: Stage II-IIIB Non-small Cell Lung Carcinoma, EGFR positive
Title and Key Inclusion/Exclusion Criteria: An Open-label, Single-arm, Phase II, Multinational, Multicentre Study to Assess the Efficacy and Safety of 5 Years of Osimertinib in Participants with Epidermal Growth Factor Receptor Mutation-Positive Stage II-IIIB Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy (TARGET).

Trial #: D533BC00001 (LATIFY)
Sponsor: AstraZeneca
Trial Sub-Type: Cytologically documented NSCLC that is locally advanced or metastatic Patients eligible for second- or later-line therapy, who must have received an anti-PD-1/PD-L1 containing therapy and a platinum-doublet regimen for locally advanced or metastatic NSCLC either separately or in combination. The patient must have had disease progression on the most recent treatment regimen.
Title and Key Inclusion/Exclusion Criteria: A Phase III, Open-label, Randomised, Multicentre Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations, and Whose Disease Has Progressed On or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy.

Trial #: D9075C00001 (PACIFIC-8)
Sponsor: AstraZeneca
Trial Sub-Type: (Stage III), Unresectable Non-small Cell Lung Cancer
Title and Key Inclusion/Exclusion Criteria: A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy (PACIFIC-8).

Trial #: D9103C00001 (PACIFIC-4)
Sponsor: AstraZeneca
Trial Sub-Type: Patients with Stage I/II Non-small Cell Lung Cancer
Title and Key Inclusion/Exclusion Criteria: A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients with Stage I/II Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515).

Trial #: D9106C00001 (Aegean)
Sponsor: AstraZeneca
Trial Sub-Type: Neoadjuvant/Adjuvant Resectable Stages II and III Non-small Cell Lung Cancer
Title and Key Inclusion/Exclusion Criteria: A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN).

Trial #: D910LC00001 (MeRmaiD-1)
Sponsor: AstraZeneca
Trial Sub-Type: NSCLC with resectable (stage II-III) disease
Title and Key Inclusion/Exclusion Criteria: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy of Adjuvant Durvalumab in Combination with Platinum-based Chemotherapy in Completely Resected Stage II-III NSCLC.

Trial #: D910MC00001 (MeRmaiD-2)
Sponsor: AstraZeneca
Trial Sub-Type: NSCLC with resectable (stage II-III) disease
Title and Key Inclusion/Exclusion Criteria: A Phase III, Randomized, Multicenter, Double-blind, Placebo-controlled Study of Durvalumab for the Treatment of Stage II-III NSCLC Patients with Minimal Residual Disease Following Surgery and Curative Intent Therapy.

Trial #: D967SC00001 (DESTINY-Lung04)
Sponsor: AstraZeneca
Trial Sub-Type:
Title and Key Inclusion/Exclusion Criteria: An Open-label, Randomized, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Trastuzumab Deruxtecan as First-line Treatment of Unresectable, Locally Advanced, or Metastatic NSCLC Harboring HER2 Exon 19 or 20 Mutations (DESTINY-Lung04).

Free Lung Cancer Screening for Eligible Participants

Since 2004, Holy Cross Hospital has participated in the International Early Lung Cancer Action Program (I-ELCAP), a research study looking at the role of low-dose CT in the detection of nodules that may be cancer.

Who should participate in I-ELCAP to be screened for lung cancer?

People who are:

At least 40 years of age
Have not undergone a chest CT in the past three years
Are current smokers or former smokers
Have a personal physician to follow up on the screening results

Why Get Screened at Holy Cross Hospital?

Holy Cross Hospital is the only hospital in the Washington, DC metropolitan area to participate in the International Early Lung Cancer Action Program. Holy Cross Hospital has been enrolling participants in this research study for the past decade.

Participants who undergo lung cancer screening at Holy Cross Hospital will have convenient access to lung care services and other resources to help reduce the risk of lung cancer and encourage a healthy lifestyle.

What to Expect at Your Lung Cancer Screening

Your lung cancer screening appointment should only take about an hour. A low-dose, non-invasive form of CT scan limits the radiation exposure to participants and produces high-resolution images. This test does not require drinking contrast fluid or intravenous injection.

Referrals

Anyone who meets the eligibility criteria for lung cancer screening can request an appointment using our online form or call 301-754-7695.